Skip to main content
SpringerLink
Log in

Thyroid Carcinoma

  • Chapter
PET-CT

  • 896 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010–1015.

    PubMed  Google Scholar 

  2. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy. J Nucl Med 2001;42:1464–1469.

    PubMed  Google Scholar 

  3. Bourguet P, Groupe de Travail SOR. Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the thyroid. Bulletin du Cancer 2003;90;S105–S109.

    PubMed  Google Scholar 

  4. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative I-131 whole body scans. J Nucl Med 1999;40:986–992.

    PubMed  Google Scholar 

  5. Clark OH, Hoelting L. Managament of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 1994;4(4):501–505.

    PubMed  Google Scholar 

  6. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy. J Nucl Med 2001;42:1464–1469.

    PubMed  Google Scholar 

  7. Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 2001;42:77–78.

    PubMed  Google Scholar 

  8. Lind P, Kresnik E, Kumnig G, et al. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Medica Austriaca. 2003;30(1):17–21.

    Article  PubMed  Google Scholar 

  9. Moog F, Linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989–1995.

    PubMed  Google Scholar 

  10. Schonberger J, Ruschoff J, Grimm D, et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12(9):747–754.

    Article  PubMed  Google Scholar 

  11. Shiga T. Comparison of 18F-FDG, 131I-Na, and 201-Tl in diagnosis of recurrent or metastatic thyroid cancer. J Nucl Med 2001;42:414–419.

    PubMed  Google Scholar 

  12. Szakall S Jr, Esik O, Bajzik G, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43:66–71.

    PubMed  Google Scholar 

  13. Van Tol KM, Jager PL, Piers DA, et al. Better yield of (18) fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12(5):381–387.

    Article  PubMed  Google Scholar 

  14. Yeo JS, Chung JK, So Y, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for i-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001;23:94–103.

    Article  PubMed  Google Scholar 

  15. Zimmer LA, McCook B, Meltzer C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128(2):178–184.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Lalitha Ramanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. PET Imaging Science Center, University of Southern California, Los Angeles, California, USA

    Peter S. Conti MD, PhD, FACNP, FACR (Professor of Radiology, Clinical Pharmacy & Biomedical Engineering, Director) & Daniel K. Cham MD, MS (Clinical Research Fellow) (Professor of Radiology, Clinical Pharmacy & Biomedical Engineering, Director) &  (Clinical Research Fellow)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Ramanna, L. (2005). Thyroid Carcinoma. In: Conti, P.S., Cham, D.K. (eds) PET-CT. Springer, New York, NY. https://doi.org/10.1007/0-387-27044-2_20

Download citation

  • DOI: https://doi.org/10.1007/0-387-27044-2_20

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-20858-9

  • Online ISBN: 978-0-387-27044-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation